Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.94
EPS est.
$-0.93
EPS surprise
-1.29%
1-day move
-4.82%
Kodiak Sciences reported a loss of $0.94 per share, slightly missing expectations. The stock reacted negatively, dropping 4.82%. Investors may be concerned about the lack of revenue information and guidance, which could indicate uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | N/A | -1.29% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Kodiak Sciences Inc. is a biotechnology company focused on developing treatments for eye diseases. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the global population ages and the demand for innovative medical solutions grows.
Last quarter
In the last quarter, Kodiak reported an EPS of -$1.04, slightly missing analyst expectations. The stock reacted positively, gaining 13.25% the following day, indicating some investor optimism despite the loss.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-4.65%
Avg 1-day reaction
-1.16%
Overall, expectations for Kodiak's upcoming earnings are uncertain due to a lack of analyst estimates. Investors are keen to see if the company can improve its financial performance and provide clarity on its product pipeline.
Bull case
If Kodiak can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a strong rally in the stock price, reflecting renewed investor confidence.
Bear case
Conversely, if the company reports wider losses or delays in its product pipeline, it may lead to a negative reaction from investors, driving the stock down.
The print will turn on these.
Q1
What is the current status of Kodiak's clinical trials for its leading product candidates?
Investors will closely watch for updates on clinical trials, as successful results could significantly boost the stock price.
Q2
How does Kodiak plan to address its ongoing losses and improve profitability?
Management's strategy for reducing losses and achieving profitability will be crucial for investor confidence and stock performance.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The Street may underestimate the potential for Kodiak's pipeline to deliver breakthrough results, which could lead to a significant upside.
Supporting evidence
The options market is pricing in a 13.1% move, indicating expectations for volatility that may not align with the company's actual performance.
Kodiak's recent stock price movements suggest a level of investor optimism that could be overlooked by analysts.
Key risk
If clinical trial results exceed expectations, it could shift the narrative dramatically.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to turn clinical advancements into financial performance.
Bull confirmed if
A report of positive clinical trial results for its leading product candidates could confirm the bull case.
Bear confirmed if
Wider-than-expected losses or delays in product development could confirm the bear case.
What the market is pricing for the move.
Implied Move
±13.1%
Historical Avg
±5.2%
The options market is pricing in a significant move of about 13.1%, suggesting that traders expect volatility around the earnings report.
Options are pricing ±10.2% while KOD has averaged ±5.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
182.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Kodiak beats expectations and raises guidance, history suggests a potential stock increase of around 1.34% on the following day.
In line / cautious
If results are in line with expectations but cautious commentary is provided, the stock may see muted movement.
Miss
If Kodiak misses expectations, history suggests a potential decline of about 1.81% the next day.
The lines on the call that would change the story.